A Phase I/II Study of Nivolumab plus or minus Ipilimumab in Combination with Multi-fraction Stereotactic Radiosurgery for Recurrent High-grade Radiation-relapsed Meningioma
Are you eligible to participate in this study?
You may be eligible for this study if you meet the following criteria:
-
Conditions: Meningioma
-
Age: Between 18 - 100 Years
-
Gender: Male or Female
-
Other Inclusion Criteria:
1) Patients must have histologically confirmed WHO grade II-III meningioma which has relapsed after prior radiation therapy with radiologically progressive or recurrent disease. 2) Patients must have measurable disease, defined as at least 1 lesion that can be accurately measured in at least one dimension as =1 cm on brain MRI but with the maximum dimension = 5 cm OR gross tumor volume < 20 cm3. 3) Patients must have at least one prior surgery with available archival formalin-fixed paraffin-embedded (FFPE) tumor blocks of the initial or recurrent meningioma.
You may not be eligible for this study if the following are true:
-
1) Patients who have had chemotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study. 2) Patients who have had radiation therapy (to the site of reirradiation) within 6 months prior to entering the study. 3) Patients who have not recovered from adverse events due to prior anti-cancer therapy (i.e., have residual toxicities > Grade 1); however, alopecia, sensory neuropathy = grade 2, or other = grade 2 not constituting a safety risk based on the investigator’s judgmentare acceptable.
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.